Low plasma levels of decoy receptor 3 (DcR3) in the third trimester of pregnancy with preeclampsia

Yeh, Chien-Yuh; Yang, Ming-Jie; Lussier, Eric C.; Tsai, Hsiao Wen; Lo, Pei-Fen; Hsieh, Shie-Liang; Wang, Peng-Hui

doi:10.1016/j.tjog.2019.03.011

Cited by 6 publications

(5 citation statements)

References 44 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…), thus inducing the production of inflammatory factors [ 37 , 38 ]. Furthermore, by binding to DR3, endogenous TL1A inhibits endothelial cell proliferation and angiogenesis in an autocrine or paracrine manner and exerts tumor-suppressive effects [ 39 , 40 ].…”

Section: Dcr3mentioning

confidence: 99%

Research Progress of DcR3 in the Diagnosis and Treatment of Sepsis

Su,

Tong,

et al. 2023

IJMS

View full text Add to dashboard Cite

Decoy receptor 3 (DcR3), a soluble glycosylated protein in the tumor necrosis factor receptor superfamily, plays a role in tumor and inflammatory diseases. Sepsis is a life-threatening organ dysfunction caused by the dysregulation of the response to infection. Currently, no specific drug that can alleviate or even cure sepsis in a comprehensive and multi-level manner has been found. DcR3 is closely related to sepsis and considerably upregulated in the serum of those patients, and its upregulation is positively correlated with the severity of sepsis and can be a potential biomarker for diagnosis. DcR3 alone or in combination with other markers has shown promising results in the early diagnosis of sepsis. Furthermore, DcR3 is a multipotent immunomodulator that can bind FasL, LIGHT, and TL1A through decoy action, and block downstream apoptosis and inflammatory signaling. It also regulates T-cell and macrophage differentiation and modulates immune status through non-decoy action; therefore, DcR3 could be a potential drug for the treatment of sepsis. The application of DcR3 in the treatment of a mouse model of sepsis also achieved good efficacy. Here, we introduce and discuss the progress in, and suggest novel ideas for, research regarding DcR3 in the diagnosis and treatment of sepsis.

show abstract

Section: Dcr3mentioning

confidence: 99%

Research Progress of DcR3 in the Diagnosis and Treatment of Sepsis

Su,

Tong,

et al. 2023

IJMS

View full text Add to dashboard Cite

show abstract

“…Significantly higher levels of LIGHT protein have been found in the maternal serum of preeclamptic patients, particularly in the third trimester (Wang et al, 2014;Hirashima et al, 2018). Also, a soluble LIGHT decoy receptor, DcR3 is present in human placental tissue and serum levels of DcR3 are significantly decreased in the third trimester of preeclamptic pregnancies (Lin and Hsieh, 2011;Hsieh and Lin, 2017;Yeh et al, 2019).…”

Section: Lightmentioning

confidence: 99%

“…Injection of LIGHT in non-pregnant C57Bl/6 mice induced high blood pressure but not proteinuria, indicating that at least some of the PE-like features in this approach are not pregnancy specific (Wang et al, 2014;Luo et al, 2016). Additionally, mice do not express DcR3; however, the lack of decoy receptor may approximate the human condition, where levels of DcR3 are significantly reduced in third trimester of human PE (Lin and Hsieh, 2011;Wang et al, 2014;Hirashima et al, 2018;Yeh et al, 2019). The LIGHT approach may be useful in studying the effect of maternal inflammation in pregnancy.…”

Section: Lightmentioning

confidence: 99%

Current State of Preeclampsia Mouse Models: Approaches, Relevance, and Standardization

2021

View full text Add to dashboard Cite

Preeclampsia (PE) is a multisystemic, pregnancy-specific disorder and a leading cause of maternal and fetal death. PE is also associated with an increased risk for chronic morbidities later in life for mother and offspring. Abnormal placentation or placental function has been well-established as central to the genesis of PE; yet much remains to be determined about the factors involved in the development of this condition. Despite decades of investigation and many clinical trials, the only definitive treatment is parturition. To better understand the condition and identify potential targets preclinically, many approaches to simulate PE in mice have been developed and include mixed mouse strain crosses, genetic overexpression and knockout, exogenous agent administration, surgical manipulation, systemic adenoviral infection, and trophoblast-specific gene transfer. These models have been useful to investigate how biological perturbations identified in human PE are involved in the generation of PE-like symptoms and have improved the understanding of the molecular mechanisms underpinning the human condition. However, these approaches were characterized by a wide variety of physiological endpoints, which can make it difficult to compare effects across models and many of these approaches have aspects that lack physiological relevance to this human disorder and may interfere with therapeutic development. This report provides a comprehensive review of mouse models that exhibit PE-like symptoms and a proposed standardization of physiological characteristics for analysis in murine models of PE.

show abstract

“…84 In pregnancy, DCR3 expression is detected in preeclamptic placentas and is elevated in the excessive inflammatory activities of PE. 85 Ching Yeh et al 86 revealed that the plasma level of DCR3 in PE patients was meaningfully lower than that of the normal pregnant group, suggesting that a potential involvement of DCR3 in normal pregnancy and the reduced levels of DCR3 may be related to immune dysregulation in PE.…”

Section: Decoy Receptormentioning

confidence: 99%

T lymphocytes and preeclampsia: The potential role of T‐cell subsets and related MicroRNAs in the pathogenesis of preeclampsia

Zolfaghari

ArefNezhad

Parhizkar

et al. 2021

American J Rep Immunol

View full text Add to dashboard Cite

Innate and adaptive immune systems have a crucial role in initiating and progressing some pregnancy disorders such as preeclampsia (PE), which is one of the pregnancy‐specific disorders that could result in neonatal and maternal morbidity and mortality. The dysregulation of the spiral artery and inadequate trophoblast invasion lead to PE symptoms through producing various inflammatory cytokines and anti‐angiogenic factors from the placenta. T lymphocytes play a special role in the epithelium and stroma of the human endometrium. CD4+ T helper (Th) cells, Th1/Th2, and Th17/T regulatory (Treg) balance mainly contribute to the establishment of a pregnancy‐favorable environment. This review examined the dysregulation of some cytokines produced from T cells, the dysregulation of the transcription factors of Th cells, the expression of chemokine receptors on T cells, as well as the effects of some factors including vitamin D on the activity of T cells, and finally, the dysregulation of various miRNAs related to T cells, which could cause PE.

show abstract

Low plasma levels of decoy receptor 3 (DcR3) in the third trimester of pregnancy with preeclampsia

Cited by 6 publications

References 44 publications

Research Progress of DcR3 in the Diagnosis and Treatment of Sepsis

Research Progress of DcR3 in the Diagnosis and Treatment of Sepsis

Current State of Preeclampsia Mouse Models: Approaches, Relevance, and Standardization

T lymphocytes and preeclampsia: The potential role of T‐cell subsets and related MicroRNAs in the pathogenesis of preeclampsia

Contact Info

Product

Resources

About